The cost-effectiveness of alternative polio immunization policies in South Africa

Vaccine

Volumn 24, Issue 29-30, 2006, Pages 5670-5678

  Griffiths, Ulla K ^a   Botham, Lindsay ^b   Schoub, Barry D ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b NATIONAL DEPARTMENT OF HEALTH   (South Africa)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

Author keywords

Cost effectiveness; Polio; South Africa; Vaccines

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; INACTIVATED VIRUS VACCINE; ORAL POLIOMYELITIS VACCINE; PERTUSSIS VACCINE;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISABILITY; DISEASE PREDISPOSITION; DRUG FORMULATION; HEALTH CARE POLICY; HEPATITIS B; HUMAN; IMMUNIZATION; INFANT; NEWBORN; NORMAL HUMAN; PARALYSIS; PERTUSSIS; POLIOMYELITIS; POLIOMYELITIS VIRUS; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SOUTH AFRICA;

CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; POLICY MAKING; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; SOUTH AFRICA; VACCINATION;

EID: 33746972806     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.05.032     Document Type: Article

References (36)

1. WHO, Polio Eradication Situation Report, Geneva, May 2005. www.polioeradication.org.
2. Progress toward poliomyelitis eradication. Southern Africa. MMWR Morb Mortal Wkly Rep 52 22 (2003) 521-524
3. Biellik R.J. Current status of polio eradication in Southern Africa. J Infect Dis 175 Suppl 1 (1997) S20-S23
4. WHO. WHO vaccine preventable diseases monitoring system. 2004 Global summary (2004), Immunization, Vaccines and Biologicals Department, WHO/IVB/2004, Geneva
5. WHO. Progress towards global poliomyetis eradication: preparation for the oral poliovirus vaccine cessation era. Wkly Epidemiol Rec 79 39 (2004) 349-355
6. WHO. Conclusions and recommendations of the Ad Hoc Advisory Committee on Poliomyelitis Eradication, Geneva, 21-22 September 2004. Wkly Epidemiol Rec 45 79 (2004) 401-408
7. In: Dowdle W.R. (Ed). The eradication of infectious diseases (1997), John Wiley & Sons, New York
8. Fenner F., Henderson D., Arita I., Jezek Z., and Ladnyi I. Smallpox and its eradication (1988), World Health Organization, Geneva
9. Henderson D.A. Countering the posteradication threat of smallpox and polio. Clin Infect Dis 34 1 (2002) 79-83
10. Technical Consultative Group to the W.H.O. on the Global Eradication of poliomyetis. "Endgame" issues for the global polio eradication initiative. Clin Infect Dis 34 1 (2002)
11. Fine P.E., Oblapenko G., and Sutter R.W. Polio control after certification: major issues outstanding. Bull World Health Organ 82 1 (2004) 47-52
12. Sutter R.W., Caceres V., and Mas Lago P. The role of routine polio immunization in the post-certification era. Bull World Health Organ 82 1 (2004) 31-39
13. WHO. Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries. WHO position paper. Wkly Epidemiol Rec 28 78 (2003) 241-252
14. Combined immunization of infants with oral inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, Thailand, and WHO Collaborative Study Group. Oral and inactivated poliovirus vaccines. Bull World Health Organ 74 3 (1996) 253-268
15. Kok P.W., Leeuwenburg J., Tukei P., van Wezel A.L., Kapsenberg J.G., van Steenis G., et al. Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya. Bull World Health Organ 70 1 (1992) 93-103
16. Lagos R., Kotloff K., Hoffenbach A., San Martin O., Abrego P., Ureta A.M., et al. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants. Pediatr Infect Dis J 17 4 (1998) 294-304
17. Simoes E., Padmini B., Steinhoff M., Jadhav M., and John T. Antibody response to two doese of inactivated poliovirus vaccine of enhanced potency. Am J Dis Child 139 (1985) 977-980
18. Edwards K., and Decker M. Pertussis vaccine. In: Plotkin O. (Ed). Vaccines. 4th ed. (2004), Saunders 471-528
19. Decker M., Edwards K., and Bogaerts H. Combination vaccines. In: Plotkin O. (Ed). Vaccines. 4th ed. (2004), Saunders 825-861
20. Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat, World Population Prospects: The 2004 Revision and World Urbanization Prospects: The 2003 Revision, http://esa.un.org/unpp.
21. Centers for Disease Control and Prevention. CDC Vaccine price list, last updated 6 April 2005. http://www.gov/nip/cdc_vac_price_list.pdf. Accessed: 9 may 2005.
22. WHO. Vaccines volume calculator: An aid for the introduction of new vaccines. Geneva: Immunization, Vaccines and Biologicals Department; WHO/V&B/01.24; 2004
23. Kou, U.K. The costs of waste management of sharps from immunization activities: a case study from South Africa, Department of Vaccines and Biologicals, Unpublished WHO report; 2001.
24. Rambøll Consultancy Services. Feasibility study for sustainable health care waste management scenarios for Gauteng. Report number 1459103 (2003), Gauteng Department of Agriculture, Conservation and Environment (DACEL), South Africa
25. WHO. Report of the interim meeting of the Technical Consultative Group (TCG) on the Global Eradication of Poliomyetis. 13-14 November 2002. WHO/V&B/03.04 (2003), Geneva, Vaccines and Biologicals Department
26. In: Murray C.J.L., and Lopez AD (Eds). The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020 (1996), Harvard School of Public Health, Boston
27. Mahadevan S., Ananthakrishna S., Srinivasan S., Nalini P., Puri R.K., Badrinath S., and Rao R.S. Poliomyelitis: 20 years-the Pondicherry experience. J Trop Med Hyg 92 6 (1989) 416-421
28. In: Zuckerman A.J., Banatvala J.E., Pattison J.R., Griffiths P.D., and Schoub B.D. (Eds). Principles and practice of clinical virology. 5th ed. (2004), John Wiley &Sons Ltd, England 476
29. WHO life tables, 2003. http://www:3.who.int/whosis/life/life_tables/.
30. Miller M.A., Sutter R.W., Strebel P.M., and Hadler S.C. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA 276 12 (1996)
31. Tucker A.W., Isaacs D., and Burgess M. Cost-effectiveness analysis of changing from live oral poliovirus vaccine to inactivated poliovirus vaccine in Australia. Aust NZ J Public Health 25 5 (2003)
32. Adam T., Evans D.B., and Murray C.J. Econometric estimation of country-specific hospital costs. Cost Eff Resour Alloc 1 1 (2003) 3
33. Pritchard C., and Sculpher M. Productivity costs: principles and practice in economic evaluation (2000), Office Health Econ, London
34. International Labour Organization, Geneva, Labour Statistics Database 1998-2005.
35. Australian Government, Department of Health and Ageing, Inactivated polio vaccine (IPV) to replace oral polio vaccine (OPV), http://immunise.health.gov.au/ipv/, accessed 31 August 2005.
36. World Health Organization. Inactivated poliovirus vaccine following oral poliovirus vaccine cessation. In: Weekly epidemiological record. Geneva: WHO; 14A, 2006.